CRT Inhibitor, iCRT5 | 1896

Cell-permeable. A potent inhibitor of the β-catenin-responsive transcription (CRT) in the nucleus. iCRT5 inhibits Wnt responsive STF16 luciferase (STF16-Luc) with an IC₅₀ of 18 nM. It acts by disrupting the interaction between β-catenin and TCF4, possibly by direct binding to β-catenin. However, it displays minimal or less prominent effect on non-canonical Wnt signaling and other pathways such as Hh, JAK/STAT, and Notch signaling.

CRT Inhibitor, iCRT5 is a potent inhibitor of the β-catenin-responsive transcription (CRT) in the nucleus. iCRT5 inhibits Wnt responsive STF16 luciferase (STF16-Luc) with an IC₅₀ of 18 nM. It acts by disrupting the interaction between β-catenin and TCF4, possibly by direct binding to β-catenin.

1896 | CRT Inhibitor, iCRT5 DataSheet

Alternate Name/Synonyms: (Z)-4-(5-(3,4-Dimethoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)butanoic acid

Appearance: Yellow solid

Formulation: N/A

CAS Number: N/A

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₆H₁₇NO₅S₂

Molecular Weight: 367.44

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A β-catenin-responsive transcription (CRT) inhibitor

MDL Number: N/A

PubChem CID: N/A

SMILES: N/A

InChi: N/A

InChi Key: N/A